|
REMODULIN® THERAPY ASSISTANCE
PROGRAM
CONSENT FORM
The Remodulin Therapy Assistance
Program is a United Therapeutics initiative to provide Remodulin patients with non-medical
assistance in support of their Remodulin therapy. This may include providing general
information about Remodulin, support group services, insurance assistance, etc.
When you submit this form, a Remodulin
Therapy Assistant (RTA) will contact you and introduce herself or himself. You will
be asked general questions, such as when you started Remodulin. The RTA will contact
you periodically and you are encouraged to contact your RTA as often as you like.
While some of the information you provide may be used for quality assurance within
United Therapeutics, none of your personal information will be shared outside United
Therapeutics. Your personal information will be maintained in a confidential manner,
in accordance with the Health Insurance Portability and Accountability Act of 1996
(HIPAA) and United Therapeutics Corporation’s
HIPAA Compliance Policy.
By submitting this form, you are
creating a no-cost relationship with your dedicated Remodulin Therapy Assistant
at United Therapeutics. Your RTA is available to help you!
If you have any questions about
the Program that you would like answered before signing this form, please feel free
to contact Robert Daye, Manager of the RTA Program (toll free 877.UNITHER or email
RTA@unither.com).
The following links to outside online resources
provide information relating to diseases for which United Therapeutics is developing
therapies, including clinical trial information, patient associations and disease
information. These links are provided for your convenience and are not intended
to suggest an affiliation between United Therapeutics and any of the organizations
maintaining these sites.
Clinical Trial Information
http://www.clinicaltrials.gov
FREEDOM
- M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension
(PAH)
FREEDOM-C:
Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or
a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial
Hypertension (PAH)
Pulmonary Hypertension
Priority Healthcare PH Information Site
http://www.phneighborhood.com
Pulmonary Hypertension Association
http://www.phassociation.org/
Peripheral Vascular
Disease/
Critical Limb Ischemia
Vascular Web Patient Information
http://www.vascularweb.org/publiceducation/patientinfo.cfm
Peripheral Vascular Surgery Society
http://www.pvss.org/
The Society for Vascular Medicine and Biology
http://www.svmb.org/
Society for Vascular Surgery
http://svs.vascularweb.org/
Vascular Disease Foundation
http://www.vdf.org/Main_Frame.asp
American Academy of Family Physicians:
“Chronic Critical Limb Ischemia: Diagnosis,
Treatment and Prognosis”
http://www.aafp.org/afp/990401ap/1899.asp
American Heart Association: Peripheral Vascular
Disease
http://www.americanheart.org/presenter.jhtml?identifier=4692
Society of Interventional Radiology: Peripheral
Vascular Disease
http://www.sirweb.org/patPub/pvdPad.shtml
|